Boryung scores $277m anti-cancer drug supply deal in China
Boryung said Tuesday it had secured a $277 million seven-year supply agreement for the original cancer drug Taxotere with China's Yifan Pharmaceutical, marking the Korean drugmaker’s largest supply contract to date. The contract marks Boryung’s first major deal since it acquired Taxotere’s glob
Boryung said Tuesday it had secured a $277 million seven-year supply agreement for the original cancer drug Taxotere with China's Yifan Pharmaceutical, marking the Korean drugmaker’s largest supply contract to date. The contract marks Boryung’s first major deal since it acquired Taxotere’s glob
💬 留言板 — 歡迎分享你的想法！
登入 Google 帳號即可留言